AgingResearch.NewsJoin free

Milestone Pharmaceuticals

CompanyCanada

Milestone Pharmaceuticals develops one asset, in phase 3 (Etripamil in atrial fibrillation with rapid ventricular response). Mostly small molecule acting on CACNA1C; based in Canada.

1
Asset
Furthest stage
Phase 3
0
Trials
1
Signal

Pipeline

1

  • Etripamil

    Blocks L-type calcium channels to slow atrioventricular conduction and reduce rapid heart rate.

    Phase 3, Small molecule, CACNA1C, atrial fibrillation with rapid ventricular response

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms1
  • Signals1
  • Similar companies3

Intelligence